The Ozempic Multiplier: Why Lifestyle Habits Still Dictate Heart Health in the GLP-1 Era
It has been three months since I started my once-weekly Ozempic injection. My blood sugar is clearly under control, and I’ve lost a little weight.
Search results for "treatment"
DR Congo’s Historic World Cup Return in Jeopardy Over U.S. Ebola Quarantine Mandate
The Democratic Republic of the Congo’s first World Cup appearance in over half a century is facing a sudden crisis. U. S.
Son Heung-min Shuts Down Alopecia Areata Rumors: “Nothing to Be Stressed About”
Football star Son Heung-min has personally pushed back against growing online rumors suggesting he is suffering from...
Daewoong Pharmaceutical Acquires U.S. Cellular Reprogramming Tech to Fast-Track Anti-Aging Therapeutics
Daewoong Pharmaceutical is accelerating its research and development into anti-aging therapeutics.
Rethinking 'Good' Cancer: How Daily Physical Activity Significantly Improves Cervical Cancer Survival
In an analysis of outcomes among cervical cancer patients—a disease often labeled a "good" cancer due to its relatively...
Age Defies the 'Oxygen-Like Woman': Lee Young-ae’s Secrets to a Sculpted Jawline at 55
Actress Lee Young-ae has once again captured the public's imagination, turning heads with a youthful appearance that...
Re-evaluating the Knife: Why Some Thyroid Cancers No Longer Require Immediate Surgery
During a routine health screening, a doctor points out a small lump on your thyroid. Additional tests deliver a jarring...
Precision in Motion: How Robot-Assisted Hip Surgery Restored Mobility for a Patient in His 60s
Initially, he could still walk. Following a fall, the 67-year-old patient, referred to as Mr.
Can Eye Health Be Reversed?... Clues Found to ‘Retinal Rejuvenation’
A potential way to return aged cells in the eye to a more youthful state has been identified.
Oscotec Ramps Up R&D: What Lies Beyond the Success of Lazertinib?
“It doesn’t end with lazertinib. Keep an eye out for the next candidate in line.” Oscotec is aggressively channeling...